Toll-like receptor 4 mediates lipopolysaccharide-induced muscle catabolism via coordinate activation of ubiquitin-proteasome and autophagy-lysosome pathways.
Cachectic muscle wasting is a frequent complication of many inflammatory conditions, due primarily to excessive muscle catabolism. However, the pathogenesis and intervention strategies against it remain to be established. Here, we tested the hypothesis that Toll-like receptor 4 (TLR4) is a master regulator of inflammatory muscle catabolism. We demonstrate that TLR4 activation by lipopolysaccharide (LPS) induces C2C12 myotube atrophy via up-regulating autophagosome formation and the expression of ubiquitin ligase atrogin-1/MAFbx and MuRF1. TLR4-mediated activation of p38 MAPK is necessary and sufficient for the up-regulation of atrogin1/MAFbx and autophagosomes, resulting in myotube atrophy. Similarly, LPS up-regulates muscle autophagosome formation and ubiquitin ligase expression in mice. Importantly, autophagy inhibitor 3-methyladenine completely abolishes LPS-induced muscle proteolysis, while proteasome inhibitor lactacystin partially blocks it. Furthermore, TLR4 knockout or p38 MAPK inhibition abolishes LPS-induced muscle proteolysis. Thus, TLR4 mediates LPS-induced muscle catabolism via coordinate activation of the ubiquitin-proteasome and the autophagy-lysosomal pathways.
Doyle
Alexander
A
Department of Integrative Biology and Pharmacology, University of Texas Health Science Center, Houston, TX 77030, USA.
Zhang
Guohua
G
Abdel Fattah
Elmoataz A
EA
Eissa
N Tony
NT
Li
Yi-Ping
YP
D000818:Animals; D001343:Autophagy / Q000187:drug effects; D015153:Blotting, Western; D002460:Cell Line; D004791:Enzyme Inhibitors / Q000494:pharmacology; D007093:Imidazoles / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008247:Lysosomes / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D018485:Muscle Fibers, Skeletal / Q000187:drug effects / Q000378:metabolism; D009124:Muscle Proteins / Q000235:genetics / Q000378:metabolism; D009132:Muscles / Q000187:drug effects* / Q000378:metabolism; D009133:Muscular Atrophy / Q000235:genetics / Q000378:metabolism; D010588:Phagosomes / Q000187:drug effects / Q000378:metabolism; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D011725:Pyridines / Q000494:pharmacology; D034622:RNA Interference; D044843:SKP Cullin F-Box Protein Ligases / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*; D051197:Toll-Like Receptor 4 / Q000235:genetics / Q000378:metabolism*; D025801:Ubiquitin / Q000378:metabolism; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism
D004791:Enzyme Inhibitors; D007093:Imidazoles; D008070:Lipopolysaccharides; D009124:Muscle Proteins; D011725:Pyridines; D051197:Toll-Like Receptor 4; D025801:Ubiquitin; C486691:Fbxo32 protein, mouse; D044843:SKP Cullin F-Box Protein Ligases; D048051:p38 Mitogen-Activated Protein Kinases; D046988:Proteasome Endopeptidase Complex; C090942:4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole
Am J Physiol Cell Physiol. 2003 Oct;285(4):C806-12
12773310
Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14440-5
11717410
Arch Surg. 1986 Aug;121(8):918-23
3729710
FEBS Lett. 2003 Jun 5;544(1-3):214-7
12782319
Cell. 1999 Mar 19;96(6):857-68
10102273
Infect Immun. 2006 Dec;74(12):6829-38
16982839
J Clin Oncol. 1995 Nov;13(11):2856-9
7595749
Pflugers Arch. 2009 Mar;457(5):989-1001
18712412
Lancet. 1999 May 29;353(9167):1838-42
10359409
Cell Metab. 2009 Dec;10(6):507-15
19945408
J Clin Invest. 1997 Jan 15;99(2):163-8
9005983
Cell. 2004 Oct 15;119(2):285-98
15479644
Int J Lab Hematol. 2007 Jun;29(3):185-9
17474895
J Leukoc Biol. 2009 Sep;86(3):557-66
19451397
Immunity. 1997 Jun;6(6):739-49
9208846
J Leukoc Biol. 2004 Sep;76(3):514-9
15178705
Int J Biochem Cell Biol. 2005 Oct;37(10):2098-114
16125113
J Clin Invest. 1994 Dec;94(6):2255-64
7989581
Clin Nutr. 2008 Dec;27(6):793-9
18718696
Int J Biochem Cell Biol. 2003 May;35(5):698-705
12672461
Muscle Nerve. 2007 Apr;35(4):411-29
17266144
Mol Cell. 2004 May 7;14(3):395-403
15125842
Autophagy. 2008 Feb;4(2):151-75
18188003
FASEB J. 2007 Jan;21(1):140-55
17116744
Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5679-84
15824322
J Cell Biochem. 2008 Oct 1;105(2):353-64
18615595
Arch Surg. 1983 Feb;118(2):167-75
6849634
J Am Soc Nephrol. 2006 Jul;17(7):1807-19
16738015
Cell Metab. 2007 Dec;6(6):472-83
18054316
Anticancer Res. 2009 Jul;29(7):2473-8
19596916
Eur Cytokine Netw. 2000 Dec;11(4):552-9
11125297
Jpn J Infect Dis. 2001 Dec;54(6):209-19
11862002
J Biol Chem. 1996 Oct 25;271(43):26690-7
8900146
Cell Metab. 2007 Dec;6(6):458-71
18054315
Cell. 2004 Apr 30;117(3):399-412
15109499
J Lab Clin Med. 1957 Nov;50(5):733-6
13476030
Clin Microbiol Rev. 2003 Oct;16(4):637-46
14557290
Mol Biol Cell. 2004 Mar;15(3):1101-11
14699058
Proc Natl Acad Sci U S A. 1982 Mar;79(6):1889-92
6952238
J Cell Biochem. 2007 Mar 1;100(4):960-9
17131360
Science. 2001 Nov 23;294(5547):1704-8
11679633
Immunity. 2007 Jul;27(1):135-44
17658277
FASEB J. 2005 Mar;19(3):362-70
15746179
J Biol Chem. 1975 Jan 10;250(1):290-8
1141208
Metabolism. 1989 Jul;38(7):634-40
2661965
Shock. 2003 Jun;19(6):538-46
12785009
Semin Immunol. 2004 Feb;16(1):3-9
14751757
Int Immunol. 2005 Jan;17(1):1-14
15585605
Am J Physiol Cell Physiol. 2009 Sep;297(3):C706-14
19625606
Autophagy. 2008 Apr;4(3):378-80
18227643
Mol Cell. 2009 May 15;34(3):259-69
19450525
Surgery. 2008 Mar;143(3):375-83
18291259
Curr Opin Clin Nutr Metab Care. 1998 Mar;1(2):217-24
10565351
Cardiovasc Diabetol. 2009 Apr 15;8:20
19368716
J Immunol. 1999 Apr 1;162(7):3749-52
10201887
Am J Physiol Cell Physiol. 2008 Oct;295(4):C986-93
18701653
Autophagy. 2008 Jan;4(1):110-2
18059159